Thymus-derived regulatory T cells (Tregs) mediate dominant peripheral tolerance and treat experimental colitis. Tregs can be expanded from patient blood. Treg cell therapy is also an attractive concept for treating Crohn’s disease. However, the stability of Tregs expanded from Crohn’s blood is unknown.
According to the study, Tregs can be expanded from the blood of patients with CD to potential target dose within 22 to 24 days. Additionally, in vitro expansion of CD45RA+ Tregs can suppress cells isolated from inflamed Crohn’s mucosa.
More articles on GI/endoscopy:
Vegetarian diet associated with reduced CRC risk
Gastroenterology technology company to know: Exalenz Bioscience
26 gastroenterologists making headlines – March 10, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.